Paradigm Biopharmaceuticals (ASX:PAR) said it entered the dosing phase of its global phase three clinical trial evaluating injectable pentosan polysulfate sodium for pain associated with knee osteoarthritis, with participants randomized and dosed in both Australia and the US, according to a Thursday Australian bourse filing.

The total target enrollment remains 466 participants, with the interim analysis planned once 50% of participants reach day 112, which is anticipated to occur in mid-2026.

All selected trial sites across Australia and the US are expected to be active and recruiting by early November. It continues to evaluate the potential inclusion of additional sites outside these two countries to further support recruitment.